ArticlePLoS neglected tropical diseases2016
Treatment Failure after Multiple Courses of Triclabendazole among Patients with Fascioliasis in Cusco, Peru: A Case Series.
Article in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- A systematic review of selected food-borne helminthiases in Southeast Asia with emphasis on anthelminthic treatment regimens.Food and waterborne parasitology · 2026Article
- Pharmacokinetic barriers to oxfendazole flukicidal efficacy.PloS one · 2026Article
- Mitochondrial genome analysis supports zoonotic transmission of triclabendazole-resistant human fascioliasis in Peru.One health (Amsterdam, Netherlands) · 2025Article
- Screening Novel Furoxan Derivatives as Potential Inhibitors Targeting Thioredoxin Glutathione Reductase ofPharmaceuticals (Basel, Switzerland) · 2025Article
- High Efficacy of Triclabendazole/Ivermectin Combination Compared to Triclabendazole Monotherapy for Treating Human Fascioliasis in Upper Egypt: A Prospective Study.Tropical medicine and infectious disease · 2025Article
- Design of a Multi-Epitope Vaccine Based onInternational journal of molecular sciences · 2025Article
- Hepatobiliary fascioliasis: A neglected re-emerging threat, its diagnostic and management challenges.World journal of gastrointestinal pathophysiology · 2025Review
- Independent origins and non-parallel selection signatures of triclabendazole resistance in Fasciola hepatica.Nature communications · 2025Article
- Development of multi-epitope Cathepsin L driven short peptide vaccine againstFrontiers in veterinary science · 2025Article
- New benzimidazole derivative compounds with in vitro fasciolicidal properties.Parasites & vectors · 2024Article
- A major locus confers triclabendazole resistance in Fasciola hepatica and shows dominant inheritance.PLoS pathogens · 2023Article
- Transcriptomic analysis supports a role for the nervous system in regulating growth and development of Fasciola hepatica juveniles.PLoS neglected tropical diseases · 2022Article
- Environmental detection ofPeerJ · 2022Article
- Human Fascioliasis (Liver Fluke Disease) in Hawai'i: Case Report and Review of Human Fascioliasis Acquired in the United States.Hawai'i journal of health & social welfare · 2021Article
- Triclabendazole Treatment Failure for Fasciola hepatica Infection among Preschool and School-Age Children, Cusco, PeruEmerging infectious diseases · 2021Article
- Towards the comprehension of fasciolosis (re-)emergence: an integrative overview.Parasitology · 2021Review
- Characterization of the Pathology, Biochemistry, and Immune Response in Kunming (KM) Mice FollowingFrontiers in cellular and infection microbiology · 2021Article
- Economic impact of the liver condemnation of cattle infected with Fasciola hepatica in the Peruvian Andes.Tropical animal health and production · 2020Article
- Drug resistance in liver flukes.International journal for parasitology. Drugs and drug resistance · 2020Review
- Treatment failure after multiple courses of triclabendazole in a Portuguese patient with fascioliasis.BMJ case reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triclabendazole is reported to be highly effective in treatment of human fascioliasis. We present 7 of 19 selected cases of human fascioliasis referred to our center in the Cusco region of Peru that failed to respond to triclabendazole. These were mostly symptomatic adults of both sexes that continued passing Fasciola eggs in the stool despite multiple treatments with 2 doses of triclabendazole at 10 mg/kg per dose. We documented the presence of eggs by rapid sedimentation and Kato Katz tests after each treatment course. We found that repeated triclabendazole courses were not effective against fascioliasis in this group of people. These findings suggest that resistance to triclabendazole may be an emerging problem in the Andes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.